Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF

Patent Number: 5527776

This patent teaches that IGF-1 together with IGF Binding Protein-3 (IGFBP-3) can be used for stimulation of hematopoiesis and specifically upregulation of erythroid production in anemic patients. This is one example of a patent covering compounds that are traditionally seen as in the domain of endocrinologists, that are applied to hematology for new uses.

The importance of IGF+IGFBP3 in stimulating hematopoiesis in vivo has to be further studied, and assessed for synergy not only with agents that are classically used for stimulation of erythroid production, but also for general stimulation of hematopoietic stem cell proliferation.

View this patent on the USPTO website.